Skip to main content
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. — Investor Relations & Filings

Ticker · RLAY ISIN · US75943R1023 US Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2026-05-21 Share Issue/Capital Cha…
Country US United States of America
Listing US RLAY

About Relay Therapeutics, Inc.

https://relaytx.com/

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming the drug discovery process. The company's approach is centered on understanding protein motion, utilizing its proprietary Dynamo® platform which integrates advanced computational and experimental methods. This platform enables the visualization of protein dynamics to design novel therapies for targets that have been historically considered intractable or 'undruggable'. Relay Therapeutics is advancing a pipeline of therapeutic candidates with an initial focus on precision oncology and genetic diseases.

Recent filings

Filing Released Lang Actions
8-K
Share Issue/Capital Change Classification · 85% confidence The document is a Form 8-K Current Report dated May 20, 2026, disclosing Item 1.01: ‘‘Entry into a Material Definitive Agreement.’’ The substantive content describes an Underwriting Agreement for an underwritten public offering of 22,916,667 shares of common stock (plus an option), including pricing, underwriting discounts, and estimated net proceeds of approximately $296.8 million. There are no financial statements or earnings data, nor any management or board changes, legal proceedings, dividends, or ESG content. Instead, it details a capital raise through a share issuance. This fits the definition of a Share Issue/Capital Change announcement (Code: SHA).
2026-05-21 English
424B5
Capital/Financing Update Classification · 90% confidence The document is a SEC prospectus supplement and accompanying prospectus filed under Rule 424(b)(5) for an offering of 22,916,667 shares of common stock. It is not an annual or interim report, nor is it a management change, earnings release, or voting results announcement. Rather, it details the terms of a capital raising transaction (share issuance), which matches the definition for Capital/Financing Update (CAP): “Updates on company fundraising, financing activities, or capital structure changes.”
2026-05-21 English
424B5
Capital/Financing Update Classification · 85% confidence The document is a preliminary prospectus supplement (Rule 424(b)(5)) and accompanying base prospectus for a registered offering of $175 million of common stock, including underwriting details, risk factors and offering terms. It is not an earnings release, financial report, or board change notice, but rather the primary offering document for a capital raise. Under our taxonomy, this falls under Capital/Financing Update (CAP).
2026-05-19 English
8-K
Regulatory Filings Classification · 82% confidence The document is a current report on Form 8-K filed with the SEC disclosing Regulation FD materials: a press release and slide presentation of clinical data. It does not contain earnings or full financials, management changes, or other specific report content. It is a general regulatory filing under the Securities Exchange Act and thus falls under the Regulatory Filings category (RNS).
2026-05-19 English
8-K - Relay Therapeutics, Inc. (0001812364) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The content includes a press release about clinical trial data and plans for a Phase 3 trial, as well as a corporate presentation. It explicitly states that the press release and presentation are furnished as exhibits and are not "filed" for purposes of Section 18 of the Exchange Act, indicating these are disclosures rather than full financial reports. The document does not contain comprehensive financial statements or detailed financial analysis but rather announces clinical data and development plans. This fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories. The document length is over 12,000 characters, so it is not a brief announcement but still does not meet criteria for financial reports or earnings releases. Therefore, the best classification is Regulatory Filings (RNS).
2026-04-27 English
10-K - RELAY THERAPEUTICS, INC. (0001812364) (Filer)
Annual Report FY 2025
2026-02-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.